Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes

What Was Tested

The trial (phase 1) is built around Semaglutide.

It had three arms (groups): Placebo (placebo comparator), one (active comparator) and one (active comparator).

Placebo saline pen administered weekly for 20 weeks.

The registry classes the interventions as drug and other.

Who Took Part

The registry lists 90 planned participants were the target.

It was open to people of any sex aged from 18 years up to 68 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male and females ages 18-60 and BMI in 30-49.9 kg/m2;. Good health as verified by screening and physical examination;. Able to read English and complete study evaluation;. Able to provide informed written and verbal consent.

The full record lists 6 inclusion and 11 exclusion criteria; among the exclusions: current use of opiates;; psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania);; current use of any anti-obesity medications;.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The Semaglutide group and the comparison group ran side by side rather than switching.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2026-10-01 with completion listed for 2031-10-31.

It ran at 1 site in United States.

Its stated primary purpose is other.

What Was Measured

It also tracked 3 secondary outcomes, for example Heavy drinking days and Average drinks per drinking day.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Semaglutide in 90 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.